Skip to main content
MEDICALSYSTEM BIOTECHNOLOGY CO., LTD logo

MEDICALSYSTEM BIOTECHNOLOGY CO., LTD — Investor Relations & Filings

Ticker · 300439 ISIN · CNE100001Z25 LEI · 3003007XTAWFVR8ASC23 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,715 across all filing types
Latest filing 2023-08-18 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300439

About MEDICALSYSTEM BIOTECHNOLOGY CO., LTD

https://www.nbmksw.com

MedicalSystem Biotechnology Co., Ltd. specializes in the research, development, production, and distribution of in vitro diagnostic (IVD) products. The company offers a comprehensive portfolio that includes biochemical reagents, chemiluminescence immunoassay systems, molecular diagnostic kits, and point-of-care testing (POCT) solutions. Its product line covers a wide range of clinical applications such as liver function, kidney function, blood lipids, and cardiovascular markers. MedicalSystem is recognized for its integrated business model, which combines the manufacturing of high-quality diagnostic instruments with a vast array of compatible reagents. Additionally, the company provides third-party medical laboratory services to healthcare institutions. By focusing on technological innovation and standardized production, MedicalSystem supports clinical laboratories in achieving accurate and efficient diagnostic results for improved patient care.

Recent filings

Filing Released Lang Actions
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2023 年半年度报告" which translates to "2023 Semi-Annual Report". It contains detailed financial data, management discussion and analysis, company overview, industry analysis, and other comprehensive information typical of an interim or quarterly report. The report covers the period from January 1, 2023 to June 30, 2023, which is a half-year period. The document length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-18 Chinese
2023年半年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by the company during the half-year period of 2023. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The content includes specifics on amounts raised, usage, balances, investment projects, approvals by the board, and compliance with regulatory requirements. It is a specialized report focusing on the management and use of capital raised by the company, not a general financial report or earnings release. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is lengthy (9912 characters) and contains substantive financial and operational details about the raised funds, not merely an announcement or certification. Therefore, the correct classification is CAP with high confidence.
2023-08-18 Chinese
2023年半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed tabular summary of non-operating fund occupation and other related party fund transactions for the half-year period of 2023. It contains specific financial data such as beginning balances, transaction amounts, interest, repayments, and ending balances for the first half of 2023. The document is 3629 characters long, which is relatively short but contains substantive financial data and analysis for a half-year period. It is not an announcement or a brief summary but a financial report with detailed accounting information. Therefore, it fits the definition of an Interim / Quarterly Report (IR), which covers comprehensive financial data for a period shorter than a full fiscal year, here specifically the half-year 2023 period. H1 2023
2023-08-18 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2023 半年度报告摘要' which translates to '2023 Semi-Annual Report Summary'. It contains detailed financial data such as revenue, net profit, earnings per share, and asset values for the half-year period. It also includes shareholder information, changes in shareholding, and important company events during the reporting period. The presence of comprehensive financial metrics and operational details for a half-year period indicates this is a financial report for a period shorter than a full fiscal year. The document length is 4016 characters, which is consistent with a summary but contains substantive financial data, not just an announcement or a link to a report. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2023
2023-08-18 Chinese
独立董事关于第四届董事会第十九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of a company regarding specific matters discussed at the 19th meeting of the 4th board of directors. It includes opinions on related party transactions, use of raised funds in the half-year period of 2023, and asset transfers to a wholly-owned subsidiary. The document is not a full financial report but rather a governance-related statement expressing independent directors' views on board meeting agenda items and compliance with laws and regulations. It does not contain comprehensive financial data or detailed financial statements. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of board-related matters and management opinions.
2023-08-18 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Meikang Bio-Technology Co., Ltd. regarding the approval of the company's 2023 semi-annual report and a special report on the use of raised funds. It states that the reports have been prepared and reviewed according to regulations and that the detailed reports are published separately on the designated disclosure website. The document itself does not contain the full semi-annual report or detailed financial data but rather announces the approval and references the location of the full reports. The document length is short (1233 characters) and fits the pattern of an announcement rather than the report itself. Therefore, it should be classified as a Regulatory Filing (RNS), which is the fallback category for such announcements that do not contain the full report or detailed financial data.
2023-08-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.